Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure

28Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Background - β-blockers prevent cardiac arrhythmias in patients with chronic heart failure and reduced left ventricular ejection fraction, including ventricular tachycardia/ventricular fibrillation (VT/VF). We hypothesized that prevention of ventricular arrhythmias by the β-blocker/sympatholytic agent bucindolol is influenced by genetic variation in adrenergic receptors. Methods and Results - From a substudy of the β-Blocker Evaluation of Survival Trial (n=1040), we identified those with the high functioning 389Arg versus the lower function 389Gly β1 adrenergic receptor variant, and the loss of function α2c322-325 adrenergic receptor deletion versus the 322 to 325 wild-type (Wt)/deletion variant. VT/VF was recorded on case report forms as an adverse event. There were 493 Arg 389 β1 receptor homozygotes (β1389 Arg/Arg) versus 547 Gly389 carriers and 207 α2c322-325 deletion carriers versus 833 homozygous Wts (α2c322-325 Wt/Wt). In all genotypes bucindolol was associated with a lower incidence of VT/VF (subhazard ratio, 0.42 [0.27-0.64]; P=0.00006). Bucindolol reduced VT/VF in β1389 Arg homozygotes (subhazard ratio, 0.26 [0.14-0.50]; P=0.00005) but not in β1389 Gly carriers (subhazard ratio, 0.60 [0.34-1.07]; P=0.09). For genotype combinations, the α2c322-325 polymorphism altered the VT/VF bucindolol response in β1389 Gly carriers, with α2c deletion genotypes associated with complete efficacy loss. A test of interaction was statistically significant (P=0.028) for the treatment group and a β1389/α2c322-325 three genotype construct, effectively identifying patients who exhibited enhanced response, no substantial response modification and loss of response. Conclusions - Bucindolol prevents VT/VF in subjects with heart failure and reduced left ventricular ejection fractions, and this effect is modulated by β1389 Arg/Gly and α2c322-325 Wt/deletion adrenergic receptor polymorphisms. © 2012 American Heart Association, Inc.

Cite

CITATION STYLE

APA

Aleong, R. G., Sauer, W. H., Robertson, A. D., Liggett, S. B., & Bristow, M. R. (2013). Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circulation: Arrhythmia and Electrophysiology, 6(1), 137–143. https://doi.org/10.1161/CIRCEP.111.969618

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free